PTGER4 and neoplasm: Inhibition of EP4 by pharmacological agents inhibits the growth of mammospheres, as determined by decreased cellularity in vitro, and in vivo treatment with EP4 antagonists reduced the tumor-forming capacity of breast cancer cells with reduced frequency of CSCs in the tumor and lung metastases (94).